Janux Therapeutics (JANX) Accumulated Depreciation & Amortization (2020 - 2025)
Janux Therapeutics (JANX) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $5.5 million as the latest value for Q1 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $5.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $5.5 million, a N/A change, with the full-year FY2024 number at $5.0 million, up 69.94% from a year prior.
- Accumulated Depreciation & Amortization was $5.5 million for Q1 2025 at Janux Therapeutics, up from $5.0 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $5.5 million in Q1 2025 to a low of $131000.0 in Q4 2021.
- A 5-year average of $2.3 million and a median of $1.9 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 641.98% in 2022, then soared 69.94% in 2024.
- Janux Therapeutics' Accumulated Depreciation & Amortization stood at $131000.0 in 2021, then surged by 641.98% to $972000.0 in 2022, then surged by 199.79% to $2.9 million in 2023, then skyrocketed by 69.94% to $5.0 million in 2024, then increased by 10.48% to $5.5 million in 2025.
- Per Business Quant, the three most recent readings for JANX's Accumulated Depreciation & Amortization are $5.5 million (Q1 2025), $5.0 million (Q4 2024), and $2.9 million (Q4 2023).